Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Blue Trust Inc.

Blue Trust Inc. lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,350 shares of the company’s stock after selling 1,009 shares during the period. Blue Trust Inc.’s holdings in Takeda Pharmaceutical were worth $137,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after buying an additional 286,052 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Takeda Pharmaceutical by 1.6% during the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after acquiring an additional 35,192 shares in the last quarter. Managed Asset Portfolios LLC boosted its stake in shares of Takeda Pharmaceutical by 0.3% during the 3rd quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock worth $23,001,000 after acquiring an additional 4,069 shares in the last quarter. Stifel Financial Corp boosted its position in shares of Takeda Pharmaceutical by 103.9% in the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after buying an additional 224,594 shares in the last quarter. Finally, Pathstone Holdings LLC grew its stake in Takeda Pharmaceutical by 1.0% in the 3rd quarter. Pathstone Holdings LLC now owns 430,676 shares of the company’s stock valued at $6,124,000 after acquiring an additional 4,280 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $14.08 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average of $13.29 and a two-hundred day moving average of $13.87. The stock has a market cap of $44.78 billion, a P/E ratio of 35.19, a PEG ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.